Nelson J. Chao, MD

Dr Chao provides his insights into the ongoing complexities that clinicians face and shaping a comprehensive understanding of the areas requiring further attention and innovation in cGvHD management.

Dr. Zeiser and Dr. Chao review ongoing clinical trials in the management of cGvHD – specifically the use of axatilimab and abatacept in SR/D cGvHD.

Experts discuss the treatments for steroid-refractory/dependent chronic Graft vs Host Disease (SR/D cGvHD), focusing on the unique mechanisms and applications of belumosudil and role of ibrutinib.

Dr. Zeiser discusses the recent data presented at ASH 2023 of the REACH3 trial.

Explore the primary treatment options for chronic Graft vs Host Disease (cGvHD) and delve into the challenges associated with prolonged steroid use, focusing on dosing strategies and adverse event management.

Two experts explore the essentials of Graft vs Host Disease (GvHD), understanding its symptoms, diagnosis, and distinguishing characteristics between acute and chronic forms.

Dr. Zeiser discusses the dynamic clinical evolution of Graft vs Host Disease (GvHD) in a concise overview, gaining insights into its progression and changing manifestations over time.

Nelson J. Chao, MD, offers closing thoughts on his treatment approach for a 35-year-old woman with chronic GVHD, and looks to the future of GVHD treatment.

A GVHD expert outlines the treatments available for patients with chronic GVHD and steroid-refractory chronic GVHD.

Nelson J. Chao, MD, gives an overview of acute and chronic GVHD, and details the classical presentation and staging process.

An expert on graft-vs-host disease discusses allogeneic stem cell transplantation, and reviews transplant conditioning and GVHD prophylaxis regimens.

Nelson J. Chao, MD, presents a patient profile of a 35-year-old woman diagnosed with chronic graft-vs-host disease, and provides his initial thoughts.

Closing out their discussion on graft-versus-host disease, participants reflect on patient prognoses and the future directions of care.

A brief discussion on the risk of treatment-induced damage when managing patients with chronic graft-versus-host disease.

Having reviewed approved treatment options for steroid-refractory, chronic GVHD, experts discuss how they would address this patient scenario.

Considerations for belumosudil and axatilimab as treatment options for steroid-refractory chronic graft-versus-host disease.

A review of treatment options approved for steroid-refractory chronic graft-versus-host disease starting with ibrutinib and ruxolitinib.

Shared insight on how to distinguish chronic GVHD from acute GVHD, as well as utilize appropriate methods to risk stratify disease.

Shifting their focus to chronic graft-versus-host disease, experts review a patient scenario and discuss the challenges in early intervention.

Experts review the prognosis of a patient with acute graft-versus-host disease and identify ways to optimize their treatment strategies.

A panel of experts discuss systemic therapy to manage a patient with acute graft-versus-host disease.

Centering discussion on a patient scenario of acute graft-versus-host disease, participants discuss nuance in disease symptomology and patient education.

Expert perspectives on the nature and occurrence of graft-versus-host disease alongside available prophylactic regimens.

Nelson J. Chao, MD, discusses a shift at Duke Cancer Institute from in-office care to home care in patients undergoing hematopoietic stem cell transplantation for hematologic malignancies.